{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:07Z","timestamp":1786982107161,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102827"],"award-info":[{"award-number":["82102827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-Young2020-0003"],"award-info":[{"award-number":["Y-Young2020-0003"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["flzh202119"],"award-info":[{"award-number":["flzh202119"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11864-023-01134-8","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T05:15:09Z","timestamp":1696828509000},"page":"1568-1579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation"],"prefix":"10.1007","volume":"24","author":[{"given":"Zhuocheng","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elene","family":"Mariamidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Aziz","family":"Sumon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Devnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rille","family":"Pihlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-5123","authenticated-orcid":false,"given":"Hongcheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"3","key":"1134_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1134_CR2","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","volume":"69","author":"M Arnold","year":"2020","unstructured":"Arnold M, Ferlay J, Van Berge Henegouwen MI, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut. 2020;69:1564\u201371.","journal-title":"Gut"},{"issue":"10125","key":"1134_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"10302","key":"1134_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"5","key":"1134_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"issue":"4","key":"1134_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrgastro.2017.162","volume":"15","author":"PSN van Rossum","year":"2018","unstructured":"van Rossum PSN, Mohammad NH, Vleggaar FP, et al. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15(4):235\u201349.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1134_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1148\/radiol.2472070999","volume":"247","author":"JH Guo","year":"2008","unstructured":"Guo JH, Teng GJ, Zhu GY, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247(2):574\u201381.","journal-title":"Radiology"},{"issue":"6","key":"1134_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(14)70131-7","volume":"15","author":"HD Zhu","year":"2014","unstructured":"Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15(6):612\u20139.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1134_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3892\/ol.2013.1466","volume":"6","author":"Z Dai","year":"2013","unstructured":"Dai Z, Zhou D, Hu J, et al. Clinical application of iodine-eluting stent in patients with advanced esophageal cancer. Oncol Lett. 2013;6(3):713\u20138.","journal-title":"Oncol Lett"},{"issue":"2","key":"1134_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0360-3016(97)00710-4","volume":"40","author":"RK Sur","year":"1998","unstructured":"Sur RK, Donde B, Levin VC, Mannell A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 1998;40(2):447\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1134_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0360-3016(02)02702-5","volume":"53","author":"RK Sur","year":"2002","unstructured":"Sur RK, Levin CV, Donde B, Sharma V, Miszczyk L, Nag S. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma\u2013an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys. 2002;53(1):127\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1134_CR12","unstructured":"Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial."},{"issue":"3","key":"1134_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1442-2050.2005.00467.x","volume":"18","author":"H Bergquist","year":"2005","unstructured":"Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18(3):131\u20139.","journal-title":"Dis Esophagus."},{"issue":"3","key":"1134_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.radonc.2013.04.008","volume":"107","author":"CD Amdal","year":"2013","unstructured":"Amdal CD, Jacobsen AB, Sandstad B, et al. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother Oncol. 2013;107(3):428\u201333.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1134_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7150\/jca.13655","volume":"7","author":"J Welsch","year":"2016","unstructured":"Welsch J, Kup PG, Nieder C, Khosrawipour V, B\u00fchler H, Adamietz IA, Fakhrian K. Survival and symptom relief after palliative radiotherapy for esophageal cancer. J Cancer. 2016;7(2):125\u201330. https:\/\/doi.org\/10.7150\/jca.13655.","journal-title":"J Cancer"},{"issue":"3","key":"1134_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.radonc.2010.09.001","volume":"97","author":"E Rosenblatt","year":"2010","unstructured":"Rosenblatt E, Jones G, Sur RK, et al. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother Oncol. 2010;97(3):488\u201394.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1134_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.brachy.2004.09.004","volume":"3","author":"R Sur","year":"2004","unstructured":"Sur R, Donde B, Falkson C, et al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy. 2004;3(4):191\u20135.","journal-title":"Brachytherapy"},{"issue":"4","key":"1134_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S2468-1253(21)00004-2","volume":"6","author":"D Adamson","year":"2021","unstructured":"\u2022 Adamson D, Byrne A, Porter C, et al. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2021;6(4):292\u2013303. This reference is of importance because it is the multicenter open-label, phase III trial demonstrated that patients with advanced esophageal cancer requiring a stent to improve dysphagia will not benefit further from addition of concurrent palliative radiotherapy.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"1134_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S2468-1253(17)30363-1","volume":"3","author":"MG Penniment","year":"2018","unstructured":"Penniment MG, De Ieso PB, Harvey JA, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018;3(2):114\u201324.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"1134_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13014-022-02019-0","volume":"17","author":"K Lan","year":"2022","unstructured":"Lan K, Chen J. Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis. Radiat Oncol. 2022;17(1):61.","journal-title":"Radiat Oncol"},{"key":"1134_CR21","first-page":"1020","volume":"9","author":"RQ Li","year":"2016","unstructured":"Li RQ, Cao L, Zhao KL, et al. Progress in diagnosis and treatment of local recurrence after radical radiotherapy for esophageal cancer. Zhong Hua Fang She Zhong Liu Xue Za Zhi. 2016;9:1020\u20134.","journal-title":"Zhong Hua Fang She Zhong Liu Xue Za Zhi"},{"issue":"10","key":"1134_CR22","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","volume":"23","author":"N Andratschke","year":"2022","unstructured":"\u2022\u2022 Andratschke N, Willmann J, Appelt AL, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022;23(10):e469\u201378. This reference is of major importance because it is the ESTRO-EORTC-endorsed consensus on classification of re-irradiation based on a Delphi process.","journal-title":"Lancet Oncol"},{"key":"1134_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11604-007-0152-4","volume":"25","author":"T Nonoshita","year":"2007","unstructured":"Nonoshita T, Sasaki T, Hirata H, et al. High-dose-rate brachytherapy for previously irradiated patients with recurrent esophageal cancer. Radiat Med. 2007;25:373\u20137.","journal-title":"Radiat Med"},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3857\/roj.2012.30.4.182","volume":"30","author":"YS Kim","year":"2012","unstructured":"Kim YS, Lee CG, Kim KH, et al. Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy. Radiat Oncol J. 2012;30:182\u20138.","journal-title":"Radiat Oncol J"},{"key":"1134_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13014-015-0358-z","volume":"10","author":"ZG Zhou","year":"2015","unstructured":"Zhou ZG, Zhen CJ, Bai WW, et al. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. Radiat Oncol. 2015;10:54.","journal-title":"Radiat Oncol"},{"key":"1134_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13014-018-1122-y","volume":"13","author":"L Hong","year":"2018","unstructured":"Hong L, Huang YX, Zhuang QY, et al. Survival benefit of re-irradiation in esophageal cancer patients with locoregional recurrence: a propensity score-matched analysis. Radiat Oncol. 2018;13:171.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1134_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13014-021-01828-z","volume":"16","author":"X Wu","year":"2021","unstructured":"Wu X, Hu X, Chen J, et al. A re-irradiation dose of 55\u201360 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy. Radiat Oncol. 2021;16(1):100.","journal-title":"Radiat Oncol"},{"key":"1134_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13014-020-01685-2","volume":"15","author":"K Zhao","year":"2020","unstructured":"Zhao K, Si Y, Sun L, et al. Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis. Radiat Oncol. 2020;15:243.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1134_CR29","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"\u2022\u2022 Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328. This reference is of major importance because it is the system of characterization and classification of oligometastatic disease developed by ESTRO OligoCare project based on a Delphi process.","journal-title":"Lancet Oncol"},{"issue":"10185","key":"1134_CR30","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"\u2022 Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138. This reference is of importance because is the international multicenter randomized phase II trial supporting that cancer patients with a controlled primary tumor and 1\u20135 oligometastases will benefit from stereotactic ablative radiotherapy.","journal-title":"Lancet"},{"issue":"2","key":"1134_CR31","doi-asserted-by":"publisher","first-page":"413e20","DOI":"10.1016\/j.athoracsur.2012.03.075","volume":"94","author":"JL Port","year":"2012","unstructured":"Port JL, Nasar A, Lee PC, et al. Definitive therapy for isolated esophageal metastases prolongs survival. Ann Thorac Surg. 2012;94(2):413e20.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"1134_CR32","first-page":"1e8","volume":"30","author":"L Depypere","year":"2017","unstructured":"Depypere L, Lerut T, Moons J, et al. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2017;30(1):1e8.","journal-title":"Dis Esophagus"},{"issue":"4","key":"1134_CR33","doi-asserted-by":"publisher","first-page":"1536e45","DOI":"10.21037\/jtd.2019.03.10","volume":"11","author":"Y Chen","year":"2019","unstructured":"Chen Y, Cheng X, Song H, et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis. 2019;11(4):1536e45.","journal-title":"J Thorac Dis"},{"issue":"2","key":"1134_CR34","doi-asserted-by":"publisher","first-page":"357e62","DOI":"10.1016\/j.athoracsur.2017.10.039","volume":"105","author":"G Ghaly","year":"2018","unstructured":"Ghaly G, Harrison S, Kamel MK, et al. Predictors of survival after treatment of oligometastases after esophagectomy. Ann Thorac Surg. 2018;105(2):357e62.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"1134_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","volume":"108","author":"Q Liu","year":"2020","unstructured":"\u2022 Liu Q, Zhu Z, Chen Y, Deng J, Ai D, Liu Q, Wang S, Wu S, Chen J, Zhao K. Phase 2 Study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(3):707\u201315. This reference is of importance because it is a phase II trial suggesting that stereotactic body radiation therapy is a well-tolerated and efficacious treatment modality for well-selected patients with oligometastatic esophageal squamous cell carcinoma.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1134_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","volume":"166","author":"TE Kroese","year":"2022","unstructured":"\u2022 Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer. 2022;166:254\u201369. This reference is of importance because it is a systematic review according to PRISMA guidelines reporting on a definition of oligometastatic esophagogastric cancer.","journal-title":"Eur J Cancer"},{"key":"1134_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2021.09.033","volume":"164","author":"Z Shi","year":"2021","unstructured":"Shi Z, Zhu X, Ke S, et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiother Oncol. 2021;164:236\u201344.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1134_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA: a cancer journal for clinicians. 2017;67(1):65\u201385. https:\/\/doi.org\/10.3322\/caac.21358.","journal-title":"CA: a cancer journal for clinicians"},{"issue":"5","key":"1134_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18(5):313\u201322. https:\/\/doi.org\/10.1038\/nrc.2018.6.","journal-title":"Nat Rev Cancer"},{"key":"1134_CR40","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"A Lugade","year":"2005","unstructured":"Lugade A, Moran J, Gerber S, Rose R, Frelinger J, Lord E. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516\u201323.","journal-title":"J Immunol"},{"issue":"7","key":"1134_CR41","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-09-2982","volume":"70","author":"T Takeshima","year":"2010","unstructured":"Takeshima T, Chamoto K, Wakita D, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70(7):2697\u2013706.","journal-title":"Cancer Res"},{"issue":"20","key":"1134_CR42","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano AE, GhasemzadehA Ali, Nirschl TR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer. 2018;24(20):5058\u201371.","journal-title":"Clin Cancer."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01134-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01134-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01134-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T05:15:04Z","timestamp":1699852504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01134-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01134-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"3 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}